Report Scope: The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market.The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023.
The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.
Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.
The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.
The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.
Report Includes: - 71 data tables and 40 additional tables - An overview of the global longevity and anti-senescence therapy market - Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 - Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa - Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process - Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics - A look at the clinical trials and expected launch of anti-senescence products - Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology
Summary Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. “Human longevity” is typically used to describe the length of an individual’s lifetime and is sometimes used as a synonym for “life expectancy” in the demography. “Anti-senescence” is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.
Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.
An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).
According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED.By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED.
An increasing geriatric population across the globe will generate huge growth prospectus to the market.
Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.
Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.
The report provides analysis based on each market segment including therapies and application.The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others.
Senolytic drug therapy held the largest market revenue share of REDACTED in 2017.By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED.
Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023.The fastest growth of the gene therapy segment is due to the Large investments in genomics.
For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.
Our reports have been used by over 10K customers, including:
Atrial Flutter Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Atrial Flutter Global Clinical Trials Review, H2, 2020" provides an overview of Atrial Flutter Clinical trials scenario.This report provides top line data relating to the clinical trials on Atrial Flutter. Report...
Osteonecrosis Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Osteonecrosis Global Clinical Trials Review, H2, 2020" provides an overview of Osteonecrosis Clinical trials scenario.This report provides top line data relating to the clinical trials on Osteonecrosis. Report...
The Asia Pacific liposome drug delivery market is expected to reach US$ 1,562.92 million in 2027 from US$ 759.81 in 2019. The market is estimated to grow with a CAGR of 9.6% from 2020-2027. The growth of the market is attributed to the some key driving factors such as high incidence of chronic diseases amongst the population, an upsurge...
Candidiasis Pipeline Overview The Q4 Candidiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Candidiasis, provides an update on the mechanism of action and targets, licensing and collaboration opportunities, company...
Dengue Fever Pipeline Overview The Q4 Dengue Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Dengue Fever, provides an update on the mechanism of action and targets, licensing and collaboration opportunities,...
Global COVID-19 Partnering report provides the full collection of COVID-19 disease deals signed between the world’s pharmaceutical and biotechnology companies since the start of 2020. This fast moving dealmaking report is updated twice monthly and sent to you by email over the 12 month subscription. Trends in...
“RELUGOLIX (TAK-385) - Emerging Insight and Market Forecast – 2030” the report provides comprehensive insights about an investigational product for Endometriosis in 7 Major Markets. A detailed picture of the RELUGOLIX (TAK-385) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan,...
Acromegaly - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2020, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape. Acromegaly is a hormonal disorder that develops when pituitary...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.